Mereo BioPharma Group Future Growth

Future criteria checks 2/6

Mereo BioPharma Group's earnings are forecast to decline at 11.7% per annum while its annual revenue is expected to grow at 53.3% per year. EPS is expected to grow by 45.8% per annum.

Key information

-11.7%

Earnings growth rate

45.8%

EPS growth rate

Biotechs earnings growth	36.7%
Revenue growth rate	53.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0A9G - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	41	-40	N/A	N/A	3
12/31/2025	16	-36	N/A	N/A	5
12/31/2024	15	-23	N/A	N/A	5
6/30/2024	1	-37	-21	-20	N/A
3/31/2024	10	-26	-21	-20	N/A
12/31/2023	10	-29	-22	-21	N/A
9/30/2023	10	-32	-34	-33	N/A
6/30/2023	9	-32	-42	-42	N/A
3/31/2023	N/A	-42	-46	-46	N/A
12/31/2022	N/A	-42	-47	-49	N/A
9/30/2022	N/A	-31	-42	-43	N/A
6/30/2022	N/A	-23	-40	-41	N/A
3/31/2022	24	-4	-25	-26	N/A
12/31/2021	49	17	-8	-7	N/A
9/30/2021	49	-10	-9	-8	N/A
6/30/2021	50	-37	-10	-10	N/A
3/31/2021	25	-131	-23	-25	N/A
12/31/2020	N/A	-224	-36	-39	N/A
9/30/2020	N/A	-198	-35	-37	N/A
6/30/2020	N/A	-177	-34	-36	N/A
3/31/2020	N/A	-111	-46	-47	N/A
12/31/2019	N/A	-46	-61	-61	N/A
9/30/2019	N/A	-41	-50	-50	N/A
6/30/2019	N/A	-40	-45	-45	N/A
3/31/2019	N/A	-41	-38	-38	N/A
12/31/2018	N/A	-41	-30	-29	N/A
9/30/2018	N/A	-42	-41	-39	N/A
6/30/2018	N/A	-44	-51	-48	N/A
3/31/2018	N/A	-50	N/A	-48	N/A
12/31/2017	N/A	-52	N/A	-43	N/A
9/30/2017	N/A	-50	N/A	-41	N/A
6/30/2017	N/A	-47	N/A	-39	N/A
3/31/2017	N/A	-41	N/A	-37	N/A
12/31/2016	N/A	-35	N/A	-37	N/A
6/30/2016	N/A	-39	N/A	-25	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0A9G is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0A9G is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0A9G is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0A9G's revenue (53.3% per year) is forecast to grow faster than the UK market (3.7% per year).

High Growth Revenue: 0A9G's revenue (53.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0A9G's Return on Equity is forecast to be high in 3 years time

Mereo BioPharma Group Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

Recent updates

Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Less than half of directors are independent

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo Biopharma Group plc Announces Board Changes

Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan

Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Less than half of directors are independent

Less than half of directors are independent

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors

Investor sentiment deteriorated over the past week

Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group

Mereo BioPharma Group plc Announces Board Changes

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Astrazeneca Reportedly Considering Take over Offer for Mereo

Investor sentiment improved over the past week

Rubric Capital Sends Letter to Mereo BioPharma

Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

High number of new directors

High number of new directors

Rubric Capital Discloses its Views on Mereo BioPharma

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Investor sentiment deteriorated over the past week

Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors

The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease

Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting

High number of new directors

High number of new directors

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Forecast to breakeven in 2025

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies